Arax Advisory Partners’s Amicus Therapeutics FOLD Stock Holding History

Arax Advisory Partners’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-686	Closed	-$9.92K	–	5227
2026 Q1	$9.92K	Buy	686 +66	+11%	+$946	﹤0.01%	2442
2025 Q4	$8.83K	Sell	620 -1,079	-64%	-$10.6K	﹤0.01%	2538
2025 Q3	$13.4K	Buy	1,699 +1,541	+975%	+$11K	﹤0.01%	2473
2025 Q2	$906	Buy	158 +87	+123%	+$561	﹤0.01%	2805
2025 Q1	$580	Buy	71 +45	+173%	+$416	﹤0.01%	2516
2024 Q4	$245	Sell	26 -68	-72%	-$707	﹤0.01%	2379
2024 Q3	$1K	Buy	+94	New	+$1.02K	﹤0.01%	2255

Other funds holding FOLD

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Arax Advisory Partners's FOLD Position: Q2 2026 in Review

Arax Advisory Partners sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 686 shares — an estimated $9.92K sold.

Arax Advisory Partners first reported a position in FOLD in Q3 2024 and held it in 7 quarters. The position peaked at $13.4K in Q3 2025. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.

Arax Advisory Partners reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
Arax Advisory Partners sold 686 Amicus Therapeutics shares in Q2 2026, an estimated $9.92K.
Arax Advisory Partners first reported a position in Amicus Therapeutics in Q3 2024 and held it in 7 quarters.
Arax Advisory Partners's Amicus Therapeutics position peaked at $13.4K in Q3 2025.
2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.